Preclinical Data Shown at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine -Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer